Todd Watanabe files SEC Form 4 disclosures for Arcutis Biotherapeutics, Inc.. They have made 6 open-market trades across 1 company since 2025, most recently 2026-08-03.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARQT | 717,203 | $20.7M |
Shares reported on the most recent Form 4, priced at the 2026-08-05 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARQT | SELL | 2026-08-03 | 2026-08-05 | $26.12 | $114K | -11.8% | -17.7% | — |
| ARQT | SELL | 2026-05-04 | 2026-05-06 | $23.61 | $75K | -12.4% | -7.2% | +13.8% |
| ARQT | SELL | 2026-03-02 | 2026-03-03 | $25.18 | $941K | -3.0% | +0.8% | -8.3% |
| ARQT | SELL | 2026-02-02 | 2026-02-04 | $25.50 | $506K | +1.6% | -8.3% | -10.5% |
| ARQT | SELL · 10b5-1 | 2025-11-21 | 2025-11-24 | $30.36 | $3.0M | +1.5% | -4.2% | -14.4% |
| ARQT | SELL | 2025-11-03 | 2025-11-05 | $24.71 | $569K | +9.4% | +30.4% | +9.4% |
| ARQT | SELL · 10b5-1 | 2025-10-28 | 2025-10-30 | $25.03 | $1.0M | -2.7% | +23.0% | +3.1% |
| ARQT | SELL · 10b5-1 | 2025-10-01 | 2025-10-03 | $19.81 | $1.5M | +8.7% | +24.5% | +45.8% |
| ARQT | SELL · 10b5-1 | 2025-09-08 | 2025-09-10 | $17.54 | $346K | -0.8% | +14.5% | +70.0% |
| ARQT | SELL | 2025-08-04 | 2025-08-05 | $14.33 | $331K | +12.2% | +7.7% | +64.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.